Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr Denis Donohue of the FDA asked pharmaceutical companies to stop using blood collected from donors likely to have high levels of antibodies to Hepatitis.

  • Read more about Dr Denis Donohue of the FDA asked pharmaceutical companies to stop using blood collected from donors likely to have high levels of antibodies to Hepatitis.

Alpha confirmed that it had "voluntarily suspended until further notice the use of cryoprecipitated material from hepatitis B surface antibody donors in the manufacture of Antihemophilic Factor (Human)."

  • Read more about Alpha confirmed that it had "voluntarily suspended until further notice the use of cryoprecipitated material from hepatitis B surface antibody donors in the manufacture of Antihemophilic Factor (Human)."

Alpha confirmed that until further notice it would 'not be using the cryoprecipitated material from plasma from hepatitis B surface antibody donors in the manufacture of Antihemophilic Factor (Human).'

  • Read more about Alpha confirmed that until further notice it would 'not be using the cryoprecipitated material from plasma from hepatitis B surface antibody donors in the manufacture of Antihemophilic Factor (Human).'

It was reported to the World Congress of Blood Transfusion (Budapest) that is was suspected in the US that an infective agent in blood concentrates resulted in people with haemophilia dying of AIDS.

  • Read more about It was reported to the World Congress of Blood Transfusion (Budapest) that is was suspected in the US that an infective agent in blood concentrates resulted in people with haemophilia dying of AIDS.

The New England Journal of Medicine carried an article suggesting the recorded cases of the principal symptoms included in the syndrome might only represent the tip of the iceberg in terms of the prevalence of conditions associated with AIDS.

  • Read more about The New England Journal of Medicine carried an article suggesting the recorded cases of the principal symptoms included in the syndrome might only represent the tip of the iceberg in terms of the prevalence of conditions associated with AIDS.

Professor Zuckerman told Michael Gillard that he had visited Immuno in Vienna, and thought it was a poor facility, which lacked medical back-up and had "dubious sources of plasma".

  • Read more about Professor Zuckerman told Michael Gillard that he had visited Immuno in Vienna, and thought it was a poor facility, which lacked medical back-up and had "dubious sources of plasma".

Dr Arthur Codd stated that it was known that viruses were transmitted in this way: "we knew there was always a risk there might be other things lurking there" adding that it had always been his advice to create a "pedigree herd" of volunteer donors in order to minimise the risk of infection. A decision was made to import commercial concentrates stating that "We could not have met demand at that time but we could have continued with the older products until Britain became self-sufficient."

  • Read more about Dr Arthur Codd stated that it was known that viruses were transmitted in this way: "we knew there was always a risk there might be other things lurking there" adding that it had always been his advice to create a "pedigree herd" of volunteer donors in order to minimise the risk of infection. A decision was made to import commercial concentrates stating that "We could not have met demand at that time but we could have continued with the older products until Britain became self-sufficient."

The last batch of Koate imported by Speywood was released by DHSS in February 1980.

  • Read more about The last batch of Koate imported by Speywood was released by DHSS in February 1980.

Speywood were informed that they could no longer sell relabelled Koate under the brand Humante as the CSM were unable to ensure the safety of the product.

  • Read more about Speywood were informed that they could no longer sell relabelled Koate under the brand Humante as the CSM were unable to ensure the safety of the product.

Speywood had a product licence to distribute Cutter's Koate, and by February 1980, Speywood later relabelled the Koate product and sold it as Humanate

  • Read more about Speywood had a product licence to distribute Cutter's Koate, and by February 1980, Speywood later relabelled the Koate product and sold it as Humanate

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 752
  • Page 753
  • Page 754
  • Page 755
  • Current page 756
  • Page 757
  • Page 758
  • Page 759
  • Page 760
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.